IL-1 Receptor Antagonist Treatment Aggravates Staphylococcal Septic Arthritis and Sepsis in Mice

Interleukin-1 receptor antagonist (IL-1Ra) is the primary therapy against autoinflammatory syndromes with robust efficacy in reducing systemic inflammation and associated organ injury. However, patients receiving IL-1Ra might be at increased risk of acquiring serious infections. To study whether IL-...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2015-07, Vol.10 (7), p.e0131645-e0131645
Hauptverfasser: Ali, Abukar, Na, Manli, Svensson, Mattias N D, Magnusson, Malin, Welin, Amanda, Schwarze, Jan-Christoph, Mohammad, Majd, Josefsson, Elisabet, Pullerits, Rille, Jin, Tao
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e0131645
container_issue 7
container_start_page e0131645
container_title PloS one
container_volume 10
creator Ali, Abukar
Na, Manli
Svensson, Mattias N D
Magnusson, Malin
Welin, Amanda
Schwarze, Jan-Christoph
Mohammad, Majd
Josefsson, Elisabet
Pullerits, Rille
Jin, Tao
description Interleukin-1 receptor antagonist (IL-1Ra) is the primary therapy against autoinflammatory syndromes with robust efficacy in reducing systemic inflammation and associated organ injury. However, patients receiving IL-1Ra might be at increased risk of acquiring serious infections. To study whether IL-1Ra treatment deteriorates Staphylococcus aureus (S. aureus) septic arthritis and sepsis in mice. NMRI mice were treated with anakinra (IL-1Ra) daily for 7 days before intravenous inoculation with S. aureus strain Newman in both arthritogenic and lethal doses. The clinical course of septic arthritis, histopathological and radiological changes of the joints, as well as the mortality were compared between IL-1Ra treated and control groups. IL-1Ra treated mice developed more frequent and severe clinical septic arthritis. Also, the frequency of polyarthritis was significantly higher in the mice receiving IL-1Ra therapy. In line with the data from clinical arthritis, both histological and radiological signs of septic arthritis were more pronounced in IL-1Ra treated group compared to controls. Importantly, the mortality of IL-1Ra treated mice was significantly higher than PBS treated controls. IL-1Ra treatment significantly aggravated S. aureus induced septic arthritis and increased the mortality in these mice.
doi_str_mv 10.1371/journal.pone.0131645
format Article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1693189164</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A420287446</galeid><doaj_id>oai_doaj_org_article_69560e62cacf48eaba94e610d8d38455</doaj_id><sourcerecordid>A420287446</sourcerecordid><originalsourceid>FETCH-LOGICAL-c796t-c9fd76a4b309fefc09b430879c5221a654ebb4749ae25da1efe1fa336cfa0a2f3</originalsourceid><addsrcrecordid>eNqNk19v0zAUxSMEYmPwDRBEQkLw0GLHjhO_IFUTfyoVTVoHr-bGuUk9pXGwncG-Pe7aTQvaA8qDrevfOck9zk2Sl5TMKSvoh0s7uh66-WB7nBPKqOD5o-SYSpbNREbY43v7o-SZ95eE5KwU4mlylAnK8oKVx8nP5WpG03PUOATr0kUfoLW98SG9cAhhi31IF23r4AoC-nQdYNhcd1ZbraFL11FldLpwYeNMMD6Fvt4VfdyaPv1mND5PnjTQeXxxWE-S758_XZx-na3OvixPF6uZLqQIMy2buhDAK0Zkg40msuKMlIXUeZZREDnHquIFl4BZXgPFBmkDjAndAIGsYSfJ673v0FmvDuF4RYVktJQxnEgs90Rt4VINzmzBXSsLRt0UrGsVuNhOh0rIXBAUmQbd8BKhAslRUFKXNSt5nkev2d7L_8ZhrCZu7TioWGpH5VFlVPJ4DSfJx8PXjdUWax1jddBNZNOT3mxUa68U56WUJIsG7w4Gzv4a0Qe1NV5j10GPdrzpk0uRi4JE9M0_6MNpHKgWYsOmb2x8r96ZqgXPSFYWnItIzR-g4lPj1uj45zUm1ieC9xNBZAL-CS2M3qvl-vz_2bMfU_btPXaD0IWNt90YjO39FOR7UDvrvcPmLmRK1G5wbtNQu8FRh8GJslf3L-hOdDsp7C-btBPQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1693189164</pqid></control><display><type>article</type><title>IL-1 Receptor Antagonist Treatment Aggravates Staphylococcal Septic Arthritis and Sepsis in Mice</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Ali, Abukar ; Na, Manli ; Svensson, Mattias N D ; Magnusson, Malin ; Welin, Amanda ; Schwarze, Jan-Christoph ; Mohammad, Majd ; Josefsson, Elisabet ; Pullerits, Rille ; Jin, Tao</creator><contributor>Gao, Hongwei</contributor><creatorcontrib>Ali, Abukar ; Na, Manli ; Svensson, Mattias N D ; Magnusson, Malin ; Welin, Amanda ; Schwarze, Jan-Christoph ; Mohammad, Majd ; Josefsson, Elisabet ; Pullerits, Rille ; Jin, Tao ; Gao, Hongwei</creatorcontrib><description>Interleukin-1 receptor antagonist (IL-1Ra) is the primary therapy against autoinflammatory syndromes with robust efficacy in reducing systemic inflammation and associated organ injury. However, patients receiving IL-1Ra might be at increased risk of acquiring serious infections. To study whether IL-1Ra treatment deteriorates Staphylococcus aureus (S. aureus) septic arthritis and sepsis in mice. NMRI mice were treated with anakinra (IL-1Ra) daily for 7 days before intravenous inoculation with S. aureus strain Newman in both arthritogenic and lethal doses. The clinical course of septic arthritis, histopathological and radiological changes of the joints, as well as the mortality were compared between IL-1Ra treated and control groups. IL-1Ra treated mice developed more frequent and severe clinical septic arthritis. Also, the frequency of polyarthritis was significantly higher in the mice receiving IL-1Ra therapy. In line with the data from clinical arthritis, both histological and radiological signs of septic arthritis were more pronounced in IL-1Ra treated group compared to controls. Importantly, the mortality of IL-1Ra treated mice was significantly higher than PBS treated controls. IL-1Ra treatment significantly aggravated S. aureus induced septic arthritis and increased the mortality in these mice.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0131645</identifier><identifier>PMID: 26135738</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Animals ; Antibiotics ; Arthritis ; Arthritis, Experimental - drug therapy ; Arthritis, Experimental - microbiology ; Arthritis, Infectious - drug therapy ; Arthritis, Infectious - microbiology ; B cells ; Comparative analysis ; Cytokines ; Cytokines - metabolism ; Disease ; Disease Models, Animal ; Drug dosages ; Drug therapy ; Experiments ; Female ; Health aspects ; Health risks ; Immune system ; Immunologi inom det medicinska området ; Immunology in the medical area ; Infection ; Infectious arthritis ; Inflammation ; Inflammation - drug therapy ; Inflammation - metabolism ; Injury prevention ; Inoculation ; Interleukin 1 ; Interleukin 1 receptor antagonist ; Interleukin 1 Receptor Antagonist Protein - therapeutic use ; Intravenous administration ; Joint diseases ; Joints - pathology ; Kidney - pathology ; Laboratories ; Macrophages, Peritoneal - metabolism ; Medical research ; Medicine ; Mice ; Mortality ; Neutrophils ; Pneumonia ; Polyarthritis ; Rheumatology ; Rodents ; Sepsis ; Sepsis - drug therapy ; Sepsis - microbiology ; Staphylococcal infections ; Staphylococcal Infections - drug therapy ; Staphylococcal Infections - microbiology ; Staphylococcus ; Staphylococcus aureus ; Staphylococcus infections ; Therapy ; TNF inhibitors ; X-Ray Microtomography</subject><ispartof>PloS one, 2015-07, Vol.10 (7), p.e0131645-e0131645</ispartof><rights>COPYRIGHT 2015 Public Library of Science</rights><rights>2015 Ali et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 Ali et al 2015 Ali et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c796t-c9fd76a4b309fefc09b430879c5221a654ebb4749ae25da1efe1fa336cfa0a2f3</citedby><cites>FETCH-LOGICAL-c796t-c9fd76a4b309fefc09b430879c5221a654ebb4749ae25da1efe1fa336cfa0a2f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489902/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489902/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793,79600,79601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26135738$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://gup.ub.gu.se/publication/219419$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><contributor>Gao, Hongwei</contributor><creatorcontrib>Ali, Abukar</creatorcontrib><creatorcontrib>Na, Manli</creatorcontrib><creatorcontrib>Svensson, Mattias N D</creatorcontrib><creatorcontrib>Magnusson, Malin</creatorcontrib><creatorcontrib>Welin, Amanda</creatorcontrib><creatorcontrib>Schwarze, Jan-Christoph</creatorcontrib><creatorcontrib>Mohammad, Majd</creatorcontrib><creatorcontrib>Josefsson, Elisabet</creatorcontrib><creatorcontrib>Pullerits, Rille</creatorcontrib><creatorcontrib>Jin, Tao</creatorcontrib><title>IL-1 Receptor Antagonist Treatment Aggravates Staphylococcal Septic Arthritis and Sepsis in Mice</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Interleukin-1 receptor antagonist (IL-1Ra) is the primary therapy against autoinflammatory syndromes with robust efficacy in reducing systemic inflammation and associated organ injury. However, patients receiving IL-1Ra might be at increased risk of acquiring serious infections. To study whether IL-1Ra treatment deteriorates Staphylococcus aureus (S. aureus) septic arthritis and sepsis in mice. NMRI mice were treated with anakinra (IL-1Ra) daily for 7 days before intravenous inoculation with S. aureus strain Newman in both arthritogenic and lethal doses. The clinical course of septic arthritis, histopathological and radiological changes of the joints, as well as the mortality were compared between IL-1Ra treated and control groups. IL-1Ra treated mice developed more frequent and severe clinical septic arthritis. Also, the frequency of polyarthritis was significantly higher in the mice receiving IL-1Ra therapy. In line with the data from clinical arthritis, both histological and radiological signs of septic arthritis were more pronounced in IL-1Ra treated group compared to controls. Importantly, the mortality of IL-1Ra treated mice was significantly higher than PBS treated controls. IL-1Ra treatment significantly aggravated S. aureus induced septic arthritis and increased the mortality in these mice.</description><subject>Animals</subject><subject>Antibiotics</subject><subject>Arthritis</subject><subject>Arthritis, Experimental - drug therapy</subject><subject>Arthritis, Experimental - microbiology</subject><subject>Arthritis, Infectious - drug therapy</subject><subject>Arthritis, Infectious - microbiology</subject><subject>B cells</subject><subject>Comparative analysis</subject><subject>Cytokines</subject><subject>Cytokines - metabolism</subject><subject>Disease</subject><subject>Disease Models, Animal</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Experiments</subject><subject>Female</subject><subject>Health aspects</subject><subject>Health risks</subject><subject>Immune system</subject><subject>Immunologi inom det medicinska området</subject><subject>Immunology in the medical area</subject><subject>Infection</subject><subject>Infectious arthritis</subject><subject>Inflammation</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - metabolism</subject><subject>Injury prevention</subject><subject>Inoculation</subject><subject>Interleukin 1</subject><subject>Interleukin 1 receptor antagonist</subject><subject>Interleukin 1 Receptor Antagonist Protein - therapeutic use</subject><subject>Intravenous administration</subject><subject>Joint diseases</subject><subject>Joints - pathology</subject><subject>Kidney - pathology</subject><subject>Laboratories</subject><subject>Macrophages, Peritoneal - metabolism</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Mice</subject><subject>Mortality</subject><subject>Neutrophils</subject><subject>Pneumonia</subject><subject>Polyarthritis</subject><subject>Rheumatology</subject><subject>Rodents</subject><subject>Sepsis</subject><subject>Sepsis - drug therapy</subject><subject>Sepsis - microbiology</subject><subject>Staphylococcal infections</subject><subject>Staphylococcal Infections - drug therapy</subject><subject>Staphylococcal Infections - microbiology</subject><subject>Staphylococcus</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus infections</subject><subject>Therapy</subject><subject>TNF inhibitors</subject><subject>X-Ray Microtomography</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk19v0zAUxSMEYmPwDRBEQkLw0GLHjhO_IFUTfyoVTVoHr-bGuUk9pXGwncG-Pe7aTQvaA8qDrevfOck9zk2Sl5TMKSvoh0s7uh66-WB7nBPKqOD5o-SYSpbNREbY43v7o-SZ95eE5KwU4mlylAnK8oKVx8nP5WpG03PUOATr0kUfoLW98SG9cAhhi31IF23r4AoC-nQdYNhcd1ZbraFL11FldLpwYeNMMD6Fvt4VfdyaPv1mND5PnjTQeXxxWE-S758_XZx-na3OvixPF6uZLqQIMy2buhDAK0Zkg40msuKMlIXUeZZREDnHquIFl4BZXgPFBmkDjAndAIGsYSfJ673v0FmvDuF4RYVktJQxnEgs90Rt4VINzmzBXSsLRt0UrGsVuNhOh0rIXBAUmQbd8BKhAslRUFKXNSt5nkev2d7L_8ZhrCZu7TioWGpH5VFlVPJ4DSfJx8PXjdUWax1jddBNZNOT3mxUa68U56WUJIsG7w4Gzv4a0Qe1NV5j10GPdrzpk0uRi4JE9M0_6MNpHKgWYsOmb2x8r96ZqgXPSFYWnItIzR-g4lPj1uj45zUm1ieC9xNBZAL-CS2M3qvl-vz_2bMfU_btPXaD0IWNt90YjO39FOR7UDvrvcPmLmRK1G5wbtNQu8FRh8GJslf3L-hOdDsp7C-btBPQ</recordid><startdate>20150702</startdate><enddate>20150702</enddate><creator>Ali, Abukar</creator><creator>Na, Manli</creator><creator>Svensson, Mattias N D</creator><creator>Magnusson, Malin</creator><creator>Welin, Amanda</creator><creator>Schwarze, Jan-Christoph</creator><creator>Mohammad, Majd</creator><creator>Josefsson, Elisabet</creator><creator>Pullerits, Rille</creator><creator>Jin, Tao</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>F1U</scope><scope>DOA</scope></search><sort><creationdate>20150702</creationdate><title>IL-1 Receptor Antagonist Treatment Aggravates Staphylococcal Septic Arthritis and Sepsis in Mice</title><author>Ali, Abukar ; Na, Manli ; Svensson, Mattias N D ; Magnusson, Malin ; Welin, Amanda ; Schwarze, Jan-Christoph ; Mohammad, Majd ; Josefsson, Elisabet ; Pullerits, Rille ; Jin, Tao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c796t-c9fd76a4b309fefc09b430879c5221a654ebb4749ae25da1efe1fa336cfa0a2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Antibiotics</topic><topic>Arthritis</topic><topic>Arthritis, Experimental - drug therapy</topic><topic>Arthritis, Experimental - microbiology</topic><topic>Arthritis, Infectious - drug therapy</topic><topic>Arthritis, Infectious - microbiology</topic><topic>B cells</topic><topic>Comparative analysis</topic><topic>Cytokines</topic><topic>Cytokines - metabolism</topic><topic>Disease</topic><topic>Disease Models, Animal</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Experiments</topic><topic>Female</topic><topic>Health aspects</topic><topic>Health risks</topic><topic>Immune system</topic><topic>Immunologi inom det medicinska området</topic><topic>Immunology in the medical area</topic><topic>Infection</topic><topic>Infectious arthritis</topic><topic>Inflammation</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - metabolism</topic><topic>Injury prevention</topic><topic>Inoculation</topic><topic>Interleukin 1</topic><topic>Interleukin 1 receptor antagonist</topic><topic>Interleukin 1 Receptor Antagonist Protein - therapeutic use</topic><topic>Intravenous administration</topic><topic>Joint diseases</topic><topic>Joints - pathology</topic><topic>Kidney - pathology</topic><topic>Laboratories</topic><topic>Macrophages, Peritoneal - metabolism</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Mice</topic><topic>Mortality</topic><topic>Neutrophils</topic><topic>Pneumonia</topic><topic>Polyarthritis</topic><topic>Rheumatology</topic><topic>Rodents</topic><topic>Sepsis</topic><topic>Sepsis - drug therapy</topic><topic>Sepsis - microbiology</topic><topic>Staphylococcal infections</topic><topic>Staphylococcal Infections - drug therapy</topic><topic>Staphylococcal Infections - microbiology</topic><topic>Staphylococcus</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus infections</topic><topic>Therapy</topic><topic>TNF inhibitors</topic><topic>X-Ray Microtomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ali, Abukar</creatorcontrib><creatorcontrib>Na, Manli</creatorcontrib><creatorcontrib>Svensson, Mattias N D</creatorcontrib><creatorcontrib>Magnusson, Malin</creatorcontrib><creatorcontrib>Welin, Amanda</creatorcontrib><creatorcontrib>Schwarze, Jan-Christoph</creatorcontrib><creatorcontrib>Mohammad, Majd</creatorcontrib><creatorcontrib>Josefsson, Elisabet</creatorcontrib><creatorcontrib>Pullerits, Rille</creatorcontrib><creatorcontrib>Jin, Tao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Göteborgs universitet</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ali, Abukar</au><au>Na, Manli</au><au>Svensson, Mattias N D</au><au>Magnusson, Malin</au><au>Welin, Amanda</au><au>Schwarze, Jan-Christoph</au><au>Mohammad, Majd</au><au>Josefsson, Elisabet</au><au>Pullerits, Rille</au><au>Jin, Tao</au><au>Gao, Hongwei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IL-1 Receptor Antagonist Treatment Aggravates Staphylococcal Septic Arthritis and Sepsis in Mice</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2015-07-02</date><risdate>2015</risdate><volume>10</volume><issue>7</issue><spage>e0131645</spage><epage>e0131645</epage><pages>e0131645-e0131645</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Interleukin-1 receptor antagonist (IL-1Ra) is the primary therapy against autoinflammatory syndromes with robust efficacy in reducing systemic inflammation and associated organ injury. However, patients receiving IL-1Ra might be at increased risk of acquiring serious infections. To study whether IL-1Ra treatment deteriorates Staphylococcus aureus (S. aureus) septic arthritis and sepsis in mice. NMRI mice were treated with anakinra (IL-1Ra) daily for 7 days before intravenous inoculation with S. aureus strain Newman in both arthritogenic and lethal doses. The clinical course of septic arthritis, histopathological and radiological changes of the joints, as well as the mortality were compared between IL-1Ra treated and control groups. IL-1Ra treated mice developed more frequent and severe clinical septic arthritis. Also, the frequency of polyarthritis was significantly higher in the mice receiving IL-1Ra therapy. In line with the data from clinical arthritis, both histological and radiological signs of septic arthritis were more pronounced in IL-1Ra treated group compared to controls. Importantly, the mortality of IL-1Ra treated mice was significantly higher than PBS treated controls. IL-1Ra treatment significantly aggravated S. aureus induced septic arthritis and increased the mortality in these mice.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>26135738</pmid><doi>10.1371/journal.pone.0131645</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2015-07, Vol.10 (7), p.e0131645-e0131645
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_1693189164
source MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS); EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry
subjects Animals
Antibiotics
Arthritis
Arthritis, Experimental - drug therapy
Arthritis, Experimental - microbiology
Arthritis, Infectious - drug therapy
Arthritis, Infectious - microbiology
B cells
Comparative analysis
Cytokines
Cytokines - metabolism
Disease
Disease Models, Animal
Drug dosages
Drug therapy
Experiments
Female
Health aspects
Health risks
Immune system
Immunologi inom det medicinska området
Immunology in the medical area
Infection
Infectious arthritis
Inflammation
Inflammation - drug therapy
Inflammation - metabolism
Injury prevention
Inoculation
Interleukin 1
Interleukin 1 receptor antagonist
Interleukin 1 Receptor Antagonist Protein - therapeutic use
Intravenous administration
Joint diseases
Joints - pathology
Kidney - pathology
Laboratories
Macrophages, Peritoneal - metabolism
Medical research
Medicine
Mice
Mortality
Neutrophils
Pneumonia
Polyarthritis
Rheumatology
Rodents
Sepsis
Sepsis - drug therapy
Sepsis - microbiology
Staphylococcal infections
Staphylococcal Infections - drug therapy
Staphylococcal Infections - microbiology
Staphylococcus
Staphylococcus aureus
Staphylococcus infections
Therapy
TNF inhibitors
X-Ray Microtomography
title IL-1 Receptor Antagonist Treatment Aggravates Staphylococcal Septic Arthritis and Sepsis in Mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T01%3A24%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IL-1%20Receptor%20Antagonist%20Treatment%20Aggravates%20Staphylococcal%20Septic%20Arthritis%20and%20Sepsis%20in%20Mice&rft.jtitle=PloS%20one&rft.au=Ali,%20Abukar&rft.date=2015-07-02&rft.volume=10&rft.issue=7&rft.spage=e0131645&rft.epage=e0131645&rft.pages=e0131645-e0131645&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0131645&rft_dat=%3Cgale_plos_%3EA420287446%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1693189164&rft_id=info:pmid/26135738&rft_galeid=A420287446&rft_doaj_id=oai_doaj_org_article_69560e62cacf48eaba94e610d8d38455&rfr_iscdi=true